Abstract:Background: The neuropilin-like, Discoidin, CUB and LCCL domain containing 2 (DCBLD2) is a transmembrane protein with an unusually long signal sequence (SS) composed of N-terminal (N) and C-terminal (C) subdomains, separated by a transition (tra) subdomain. DCBLD2 interacts with VEGFR-2 and regulates VEGF-induced endothelial cell signaling, proliferation and migration, as well as angiogenesis. The exact mechanisms by which DCBLD2 interacts with VEGFR2 to modulate VEGF signaling remain unclear. Methods: Searching for VEGFR2 interacting DCBLD2 domains, we generated various constructs containing different DCBLD2 domain combinations and conducted co-immunoprecipitation and signaling studies in HEK 293T and endothelial cells. Several peptides were synthesized based on the identified domain, and their effect on VEGF signaling was assessed in vitro in cell culture and in vivo using matrigel plug and corneal micropocket assays. The effect of the lead peptide was further evaluated using a murine hindlimb ischemia model. Results: DCBLD2 SS interacted with VEGFR2 and promoted VEGF signaling. SS was not cleaved in the mature DCBLD2 and its hydrophobic transmembrane 'traC' segment, but not the 'N' subdomain, was involved in DCBLD2-VEGFR2 interaction. The smallest unit in DCBLD2 SS that interacts with VEGFR2 was the L5VL5 sequence. Even after the central valine was removed, the L10 sequence mimicked the DCBLD2 SS traC's effect on VEGF-signaling, while shorter or longer poly-leucine sequences were less effective. Finally, a synthetic traC peptide enhanced VEGF signaling in vitro, promoted VEGF-induced angiogenesis in vivo, and improved blood flow recovery following hindlimb ischemia. Conclusion: DCBLD2 SS along with its derivative peptides can promote VEGFR2 signaling and angiogenesis. Synthetic peptides based on DCBLD2 SS hold promise as therapeutic agents for regulating angiogenesis. Importantly these findings refine the traditional view of signal sequences as mere targeting elements, revealing a role in cellular signaling. This opens new avenues for research and therapeutic strategies.

Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor

Design and In Silico Evaluation of a Novel Cyclic Disulfide-Rich anti-VEGF Peptide as a Potential Antiangiogenic Drug

In Silico designed cell-penetrating anti-cancer peptide specifically inhibits VEGF-A expression

Structural insights into molecular-targeting helix-loop-helix peptide against vascular endothelial growth factor-A

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Inhibition of Angiogenesis by a Novel Small Peptide Consisting of the Active Fragments of Platelet Factor-4 and Vasostatin

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

A Novel Peptide Specifically Binding to VEGF Receptor Suppresses Angiogenesis in Vitro and in Vivo

Regulation of angiogenesis by signal sequence-derived peptides

Peptide Functionalized Targeting Liposomes: for Nanoscale Drug Delivery Towards Angiogenesis.

A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics

Structure-activity relationship study of a small cyclic peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor interaction with Neuropilin-1

Evaluating Angiogenic Potential of Small Molecules Using Genetic Network Approaches

Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy Via Blocking Vascular Endothelial Growth Factor Signaling.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth

Design, SAR, Angiogenic Activities Evaluation and Pro-Angiogenic Mechanism of New Marine Cyclopeptide Analogs.

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

The multifaceted world of angiogenesis control

Periplasmic Expression Optimization of VEGFR2 D3 Adopting Response Surface Methodology: Antiangiogenic Activity Study.

Development of Hybrid Aptamers-Engineered PROTACs for Degrading VEGF165 in Both Tumor- and Vascular Endothelial Cells